Skip to main content
. Author manuscript; available in PMC: 2018 Jan 3.
Published in final edited form as: Cell Rep. 2017 Dec 26;21(13):3754–3766. doi: 10.1016/j.celrep.2017.11.106

Figure 2. Mammalian target of rapamycin (mTOR) pathway and identified pathogenic mutations.

Figure 2

Schematic of the mTOR pathway annotated with pathogenic mutations identified by our lab (this study and our previous studies (D’Gama et al., 2015; Poduri et al., 2012)). Somatic mutations are in boldface. FCD: focal cortical dysplasia; HME: hemimegalencephaly, PMG: polymicrogyria. See also Table S3 and S4.